Triad Company Gets FDA Approval To Market Cornea Transplant Device

7:57 PM, Feb 22, 2011   |    comments
  • Courtesy: Ocularsystemsinc.com
  • Ocular Systems grew from one worker to a staff of 14 in four years.
    
  • Share
  • Print
  • - A A A +

Winston-Salem, NC-- Tuesday, the Federal Drug Administration (FDA) approved marketing for a company located in Piedmont Triad Research Park. Ocular Systems, Inc. (OSI) announced they received the FDA clearance to market EndoSerter.

EdnoSerter is the company's device for inserting replacement cells into the eye during a type of corneal transplant. The device, was invented in Winston-Salem and is manufactured in the PTRP Park. OSI has already been marketing it in Europe and Canada. The EndoSerterâ„¢ is used for a type of corneal transplant known as endothelial keratoplasty, which is the treatment of choice when patients need to have the thin layer of endothelial cells replaced, but don't require a full corneal transplant.

The device inserts cells into the eye, protecting the delicate corneal tissue from damage. Previously, doctors used forceps to grip the cornea, which could crush the tissue. The device is designed to result in a smaller incision, no sutures, and reduce operating time.

"Winning device approval from the FDA is a major achievement and milestone for Ocular Systems, Inc.," said Doug Edgeton, President, Piedmont Triad Research Park. "This latest development demonstrates the collaborative benefits park companies derive from working together in a supportive research environment with world class facilities." "Cathtek, another park company, designed and tested the device which it manufactures under contract with OSI," added Edgeton.

To learn more about Ocular Systems Inc. click here

Related Stories:

-- WFMY featured Ocular System in July 2009 when they waiting on FDA Approval for the device.

-- Local Doctor Invents New Surgical Tool

WFUBMC/WFMY News 2

Most Watched Videos